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ABSTRACT  
To grade the long-term benefit of anticancer agents, the American Society of Clinical 
Oncology Value Framework (ASCO-VF) awards tail-of-the-curve bonus points by using 
milestone survival at twice the median control survival. Here we propose an alternative, late-life 
expectancy that we defined as the area under the Kaplan-Meier curve from median control 
survival to the end of follow-up. We analyzed all indications of immune checkpoint inhibitors 
with survival data and found that nine indications out of 13 (69%) qualified for ASCO-VF tail of 
the curve bonus points either in progression-free or overall survival. Our proposed score 
recognized a long-term benefit not captured by the ASCO-VF, for example, for CHECKMATE-
66 where twice the median overall survival was not reached. We found that nivolumab was 
associated with an increase of 65% (95% CI: 39–90) in OS late-life expectancy, which highlights 
its important long-term benefit. In conclusion, the ASCO-VF could be improved with the use of 
late-life expectancy.   
 
Key Words: Relative Value Scales; Prescription Drugs; Melanoma; Non-small Cell Lung 
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Immune checkpoint inhibitors (ICIs) have raised hopes for durable survival.1,2 For 
assessing the value of anti-cancer drugs, the American Society of Clinical Oncology Value 
Framework (ASCO-VF) recognizes the long-term benefit by awarding tail-of-the-curve bonus 
points using milestone survival at twice the control median survival. 3 This approach may have 
some drawbacks. First, milestones only reflect one point of the survival curve. 4 Second, the 
milestone is not always reached with a short follow-up. Finally, dichotomization  represents a 
loss of information5 and some drugs could fall short of the cut-off. Alternative treatment effect 
measures that could better estimate the magnitude of a drug’s clinical benefit include the ratio of 
life expectancy (or restricted mean survival times). 6,7 To quantify the long-term benefit of ICIs, 
Horiguchi et al. recently suggested using the area under the Kaplan-Meir curve between two 
milestones. 8  Here, building on their idea, we propose a measure to quantify the long-term 
benefit of anticancer agents, the late-life expectancy, which we defined as the area under the 
Kaplan-Meier curve from median survival time in the control arm to the end of the follow-up. 
 We included all FDA-approved ICI indications for treatment of solid tumors from March 
2011 to June 11, 2018. We used data from published reports of pivotal trials submitted to the 
FDA and first classified results from each trial for tail-of-the-curve bonus points. In ASCO-VF3, 
tail-of-the-curve bonus points are awarded with an improvement of at least 50% in survival 
provided the survival in the control group was at least 20%. Bonus points are 20 points for 
overall survival (OS) and 16 for progression-free survival (PFS). For indications, in an overview 
of recently FDA-approved cancer drugs, the ASCO-VF total score ranged from 3.4 to 66.5 
points.10 
 We then assessed long-term survival by computing, for each treatment arm, the late-life 
expectancy (LLE) as defined above. We reconstructed individual patient data (IPD) from the 
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digitalized curves11 and then computed LLE with the R surv2sampleComp package. 12 Because 
the median survival and the end of follow-up are not constants, we used non-parametric 
bootstrap with 999 replicates and computed the confidence interval (CI) with the bias-corrected 
and accelerated bootstrap techniques. Finally, we computed the ratio of LLE between 
experimental and control arms. Figure 1 exemplifies these calculations for the Checkmate 057 
trial.13  
 Finally, we proposed a scoring frame based on the ratios of LLEs. This formula was 
created such that it gives 20 points for OS (16 points for PFS) for a ratio of LLEs > 1.5 (to mimic 
the 50% relative difference in milestone survival that the ASCO-VF uses) and 0 points for a ratio 
≤ 1 and a bonus proportional to the ratio between 1 and 1.5 (with 20% lower scores for PFS as in 
the ASCO-VF). 
 From 2011 to June 11, 2018 the FDA approved six ICIs (ipilimumab, pembrolizumab, 
nivolumab, avelumab, atezolizumab, and durvalumab) in 27 indications (Supplementary Table 
1). Half of the indications (14/27, 52%) were based on trials not reporting OS or PFS. Because 
the ASCO-VF requires OS or PFS data, we analyzed data for 13 trials (plus the updated analysis 
for Checkmate-057). Four out of 13 indications (31%) reached the threshold for long-term 
benefit by the ASCO-VF in PFS (Supplementary Figure 1) and six indications out of 12 (50%) in 
OS (Figure 2).  Overall, nine indications out of 13 (69%) qualified for ASCO-VF tail of the 
curve bonus points either in PFS or OS. This finding is different from that of a previous study in 
which only 3 out of 10 indications were awarded bonus points. 14 The difference could be 
explained by the fact that we use Kaplan-Meier curves to estimate milestone survival in contrast 
of the previous study that used the proportion of patients still at risk at a given time. 15 
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 LLEs ratios and derived scores are depicted in Figure 2 for OS and in Supplementary 
Figure 1 for PFS. LLEs ratios ranged from 1.18 (Checkmate-025) to 1.89 (MDX010-20) for OS 
and from 1.28 (Checkmate-214) to 3.35 (MDX010-20) for PFS. For two indications, median 
control OS was not reached. Maturity of survival data is indeed a crucial point. A sufficient 
follow-up is necessary to observe medians and because high censoring will result in unstable 
estimates. Indeed, analyses of the same trial at different updates could yield very different 
estimates of the drug benefit. However, there is also a need to grade the long-term benefit as 
early as possible (e.g. for reimbursement decision). In our proposal, we not only give a score but 
also the ratio of LLE itself with its confidence interval so that one can directly assess the 
certitude around the estimate. It would be of great interest if the medical community could 
define, for each indication, the time point beyond which the treatment benefit is likely to remain 
stable. When we observe median control survival but not twice the median, calculation with our 
proposal is still possible. In Checkmate 66, no bonus points were awarded in OS because twice 
the median survival was not reached,16 but our analysis found a ratio of LLEs of 1.65 (95% CI: 
1.39 to 1.90) and a score of 20 points, which highlight the important long-term benefit of 
nivolumab. However, 16 bonus points were awarded in PFS in the ASCO-VF and thus the 
difference is only of 4 points at the indication level.  
We showed that the use of LLEs ratios may provide a fine-grained assessment of long-
term benefit.  However, we only proposed a scoring to be further discussed and improved by the 
oncology community. For instance, to reward more precise studies, statistical significance could 
be easily incorporated in our approach, by assigning a null score for indications without a 
significant result or by using the lower bounds of the 95% CI instead of the point estimate to 
reward more precise studies. Further improvements could also considerate incorporate absolute 
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magnitude of long term benefit in addition to relative effect. Our approach requires reconstructed 
(or original) IPD and re-analysis of these data, which might be a limitation of our approach.  
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Figure Legends 
Figure 1. Illustration of Late-life Expectancy Computation Based on Data from the 
CHECKMATE-057 trial. HR, hazard ratio; OS, overall survival; RMST, restricted mean survival 
times 
Figure 2. Association Between Ratios of Late-life Expectancy and Tail-of-the-curve Bonus Points 
Within The ASCO-VF for Overall Survival. Note: There are only 12 indications (13 analyses 
with the CHECKMATE-057 update) represented because there was no overall survival data for 
PACIFIC study (Durvalumab in maintenance therapy of NSCLC). 
 
Abbreviations: NSCLC, non-small-cell lung cancer; RCC, renal cell carcinoma.  
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Online-only Table 1. Indications for Immune Checkpoint Inhibitors Approved by the US Food and Drug Administration (FDA) from 
March 2011 to May 2018. 
Drug Indication Line FDA approval 
year 
Primary 
endpoint 
RCT for FDA 
approval 
Name of pivotal RCT 
used to assess long-
term benefit 
Ipilimumab Melanoma First 2015 ORR No NA 
Pembrolizumab Melanoma Second 2014 ORR No NA 
Pembrolizumab NSCLC Second 2015 ORR No NA 
Pembrolizumab HNSCC Second 2016 ORR No NA 
Pembrolizumab NSCLC First 2017 ORR No NA 
Pembrolizumab MSI-H Second 2017 ORR No NA 
Nivolumab Melanoma Second 2014 ORR No NA 
Nivolumab Urothelial carcinoma Second 2017 ORR No NA 
Nivolumab Hepatocellular 
Carcinoma 
Second 2017 ORR No NA 
Nivolumab MSI-H Second 2017 ORR No NA 
Atezolizumab Urothelial carcinoma Second 2016 ORR No NA 
Avelumab Merkel cell carcinoma Second 2017 ORR No NA 
Avelumab Urothelial carcinoma Second 2017 ORR No NA 
Durvalumab Urothelial carcinoma Second 2017 ORR No NA 
Ipilimumab Melanoma Second 2011 OS Yes MDX010-20 
Pembrolizumab Melanoma First 2015 OS Yes KEYNOTE-006 
Pembrolizumab Urothelial carcinoma  Second 2017 OS Yes KEYNOTE-045 
Nivolumab Melanoma First 2016 OS Yes CHECKMATE-066 
Nivolumab Renal cell carcinoma Second 2015 OS Yes CHECKMATE-025 
Nivolumab Squamous-cell 
NSCLC  
Second 2015 OS Yes CHECKMATE-017 
Nivolumab Non-squamous 
NSCLC  
Second 2015 OS Yes CHECKMATE-057 
Nivolumab HNSCC Second 2016 OS Yes CHECKMATE-141 
Atezolizumab NSCLC Second 2016 OS Yes OAK 
Pembrolizumab NSCLC First 2016 PFS Yes KEYNOTE-024 
Durvalumab NSCLC Maintenance 2018 PFS/OS Yes PACIFIC 
Pembrolizumab NSCLC Second 2015 PFS/OS Yes KEYNOTE-010 
Nivolumab + 
ipilimumab 
Renal cell carcinoma First 2018 PFS/OS Yes CHECKMATE-214 
RCT, randomized controlled trial; NSCLC, non-small-cell lung cancer; HNSCC, head and neck squamous cell carcinoma; MSI-H, high level microsatellite 
instability; OS, overall survival; PFS, progression-free survival; ORR, objective response rate; NA, not available 
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Supplemental Figure 1. Association Between 
Ratios of Late-life Expectancy and Tail-of-the-
curve Bonus Points Within The ASCO-VF for 
Progression-Free Survival
Abbreviations: NSCLC, non-small-cell lung cancer; RCC, renal cell 
carcinoma, T2, twice the median control survival. 
